Bank of America Corp DE Has $80.36 Million Stake in Elanco Animal Health Incorporated $ELAN

Key Points

• Bank of America increased its Elanco Animal Health stake by 38% in the first quarter, acquiring 924,032 additional shares for a total position valued at approximately $80.36 million.
• Elanco’s latest quarterly results exceeded expectations, with adjusted earnings of $0.34 per share and revenue of $1.37 billion, up 10.2% year over year. The company issued full-year 2026 EPS guidance of $1.10 to $1.16.
• Analysts maintain a “Moderate Buy” consensus rating, with an average price target of $29.09 versus the stock’s reported price of $22.06; company insiders also recently purchased shares.

Bank of America Corp DE grew its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 38.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,358,215 shares of the company's stock after buying an additional 924,032 shares during the period. Bank of America Corp DE owned approximately 0.67% of Elanco Animal Health worth $80,362,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ELAN. NewEdge Advisors LLC boosted its position in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock worth $25,000 after purchasing an additional 627 shares during the period. Root Financial Partners LLC grew its stake in Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock valued at $40,000 after buying an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. bought a new position in Elanco Animal Health in the 4th quarter worth $41,000. Torren Management LLC bought a new position in Elanco Animal Health in the 4th quarter worth $46,000. Finally, Bessemer Group Inc. lifted its position in Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company's stock worth $50,000 after acquiring an additional 525 shares during the last quarter. Institutional investors own 97.48% of the company's stock.

Insider Activity

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 4,971 shares of the business's stock in a transaction on Friday, May 15th. The stock was purchased at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the transaction, the chief executive officer owned 171,971 shares in the company, valued at $3,454,897.39. This trade represents a 2.98% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rajeev A. Modi acquired 4,911 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the purchase, the insider owned 160,812 shares of the company's stock, valued at approximately $3,272,524.20. This represents a 3.15% increase in their position. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by corporate insiders.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $22.06 on Monday. The business has a 50 day simple moving average of $24.70 and a 200 day simple moving average of $24.08. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The company has a market capitalization of $11.02 billion, a PE ratio of -53.80, a price-to-earnings-growth ratio of 1.32 and a beta of 1.67. Elanco Animal Health Incorporated has a one year low of $16.15 and a one year high of $27.98.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.31 billion. During the same period in the prior year, the business posted $0.26 earnings per share. The business's revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Analyst Ratings Changes

ELAN has been the subject of a number of recent analyst reports. KeyCorp upped their price target on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday. TD Cowen boosted their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, June 18th. Weiss Ratings raised Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, July 31st. JPMorgan Chase & Co. increased their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, May 7th. Finally, UBS Group raised their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $29.09.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source